What is AstraZeneca?
Headquartered in the United Kingdom, AstraZeneca operates at the intersection of cutting-edge science and commercial scale. The company specializes in the discovery, development, and delivery of prescription medicines, with a primary focus on Oncology and BioPharmaceuticals. Its diverse portfolio spans critical therapeutic areas, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. By integrating advanced research methodologies with a global commercial infrastructure, AstraZeneca maintains a competitive edge in the highly regulated and innovation-driven pharmaceutical landscape, consistently delivering therapeutic solutions that address significant unmet patient needs.
How much funding has AstraZeneca raised?
AstraZeneca has raised a total of $4.7B across 3 funding rounds:
Other Financing Round
$1B
Other Financing Round
$168M
Unspecified
$3.5B
Other Financing Round (2020): $1B with participation from Barda Ltd
Other Financing Round (2021): $168M led by Vaccitech Limited, Oxford Sciences Enterprises, M&G plc, and Gilead Sciences Inc
Unspecified (2024): $3.5B, investors not publicly disclosed
Key Investors in AstraZeneca
Oxford Sciences Enterprises
An independent investment firm that partners with the University of Oxford to found, fund, and build transformational businesses based on world-class research.
Vaccitech Limited
A clinical-stage biopharmaceutical company focused on the development of novel immunotherapies and vaccines for infectious diseases and cancer.
M&G plc
A leading international savings and investment business that provides asset management and insurance solutions to a global client base.
What's next for AstraZeneca?
With the recent strategic investment, AstraZeneca is well-positioned to scale its clinical development programs and expand its footprint in emerging therapeutic markets. The company's forward-looking strategy emphasizes the integration of digital health technologies and precision medicine to enhance patient outcomes. As the firm moves into its next phase of growth, the focus will likely remain on optimizing its R&D efficiency and strengthening its pipeline through both internal innovation and strategic partnerships. This capital deployment will be instrumental in maintaining the company's leadership in Oncology and BioPharmaceuticals, ensuring that it remains at the forefront of medical advancement while delivering sustainable value to its stakeholders.
See full AstraZeneca company page
